Kalamazoo, MI (PRWEB) May 01, 2015
Armune BioScience announced today that the validation study for Apifiny™ has been published in the April 2015 issue of the peer-reviewed journal, Translational Oncology (http://www.transonc.com). The study results represent another confirmation of the potential clinical insight available from the company’s proprietary autoantibody technology for use in the risk assessment of prostate cancer.
Armune BioScience initiated the national availability of Apifiny earlier this month through its CLIA registered laboratory in Ann Arbor. Apifiny is the only cancer specific, non-PSA blood test that may aid clinicians in the detection of prostate cancer.
Armune develops and commercializes autoantibody technology licensed from the University of Michigan that was developed under the direction of Arul Chinnaiyan, MD, PhD. Dr. Chinnaiyan commented, “Our research team is pleased to see the continued progress being made with the autoantibody technology from our original work. There are a number of challenges clinicians face with effectively diagnosing prostate cancer and this recently published data on Apifiny highlights the potential clinical insight available from this new diagnostic offering.”
“The proprietary technology of Armune BioScience has significant potential to meet an area of large unmet need in prostate cancer diagnostic testing,” said David A. Esposito, President and CEO of Armune. “Our team is currently responding to a great deal of interest in Apifiny from clinicians and we look forward to disseminating this important study as part of our educational efforts to the medical community.”
Armune officially opened its CLIA laboratory for business earlier this month and has been handling a high volume of requests from clinicians and reference laboratories seeking access to Apifiny — the only cancer specific, non-PSA blood test that may aid clinicians in the detection of prostate cancer. Clinicians and laboratories interested in gaining access to Apifiny should call 844-427-6863 or request information from the company’s website at http://www.armune.com.
Armune continues to raise funds through its current Series A round of investment to support the growth of the business. Interested investors should contact Eli Thomssen, Chief Business Officer, at elthomssen[at]armune.com or by telephone, 269-491-6431.
About CLIA (http://www.cms.gov/clia)
The Clinical Laboratory Improvement Amendments of 1988 (CLIA) regulations include federal standards applicable to all U.S. facilities or sites that test human specimens for health assessment or to diagnose, prevent, or treat disease. CDC, in partnership with CMS and FDA, supports the CLIA program and clinical laboratory quality.
About Translational Oncology (http://www.transonc.com)
Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.
About Armune BioScience (http://www.armune.com)
Armune BioScience, Inc. is a medical diagnostics company that develops and commercializes unique proprietary technology exclusively licensed from the University of Michigan for diagnostic and prognostic tests for prostate, lung and breast cancers. The company was founded by the Apjohn Group, LLC (http://www.apjohngroup.com), a business accelerator founded by experienced health care executives that brings together valuable resources of management talent and angel/seed financing, and a group of experienced life science professionals. Armune was incorporated as a Delaware Corporation with corporate headquarters in Kalamazoo, MI and a research and commercial laboratory in Ann Arbor, MI.